Sarepta Therapeutics, Inc. (SRPT) Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Comparison

Company

Score

Quality

Valuation

Financial

Technical

Incyte Corp.

Vertex Pharmaceuticals, Inc.

Alnylam Pharmaceuticals, Inc.

Regeneron Pharmaceuticals, Inc.

Zoetis, Inc.

Sarepta Therapeutics, Inc.

Royalty Pharma Plc

Walgreens Boots Alliance, Inc.

Viatris, Inc.

Horizon Therapeutics Plc

Seagen Inc.

Why is Sarepta Therapeutics, Inc. ?

The company has declared negative results in Mar'2025 after 7 consecutive positive quarters

PRE-TAX PROFIT(Q) At USD -62.77 MM has Fallen at -293.3%
NET PROFIT(Q) At USD -48.66 MM has Fallen at -251.63%
RAW MATERIAL COST(Y) Grown by 26.71% (YoY)

Risky -

The stock is trading risky as compared to its average historical valuations
Over the past year, while the stock has generated a return of -76.93%, its profits have fallen by -166%

Consistent Underperformance against the benchmark over the last 3 years

Along with generating -76.93% returns in the last 1 year, the stock has also underperformed S&P 500 in each of the last 3 annual periods

Real-Time Research Report

Verdict Report

How much should you sell?

All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is Sarepta Therapeutics, Inc. for you?

High Risk, Low Return

Absolute

Risk Adjusted

Volatility

Sarepta Therapeutics, Inc.

-68.86%

-0.82

104.12%

S&P 500

13.68%

0.71

19.28%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

37.28%

EBIT Growth (5y)

13.21%

EBIT to Interest (avg)

-8.03

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

0.54

Sales to Capital Employed (avg)

0.73

Tax Ratio

51.28%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

100.00%

ROCE (avg)

ROE (avg)

1.18%

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

1.32

EV to EBIT

-22.48

EV to EBITDA

-91.71

EV to Capital Employed

1.29

EV to Sales

0.80

PEG Ratio

Dividend Yield

ROCE (Latest)

-5.72%

ROE (Latest)

-6.58%

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Mildly Bullish

Bearish

RSI

No Signal

Bullish

Bollinger Bands

Mildly Bearish

Moving Averages

Bearish (Daily)

KST

Bearish

Dow Theory

Mildly Bearish

OBV

Mildly Bullish

Mildly Bearish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

12What is working for the Company

OPERATING CASH FLOW(Y)

Highest at USD -257.42 MM

NET SALES(9M)

At USD 1,755.3 MM has Grown at 41.15%

NET PROFIT(HY)

Higher at USD 111.51 MM

DEBTORS TURNOVER RATIO(HY)

Highest at 4.56 times

-20What is not working for the Company

PRE-TAX PROFIT(Q)

At USD -62.77 MM has Fallen at -293.3%

NET PROFIT(Q)

At USD -48.66 MM has Fallen at -251.63%

RAW MATERIAL COST(Y)

Grown by 26.71% (YoY

CASH AND EQV(HY)

Lowest at USD 1,651.13 MM

NET SALES(Q)

Lowest at USD 399.36 MM

INTEREST(Q)

Highest at USD 7.57 MM

Here's what is working for Sarepta Therapeutics, Inc.

Operating Cash Flow

Highest at USD -257.42 MM and Grown

In each year in the last three years

MOJO Watch

The company has generated higher cash revenues from business operations

Operating Cash Flows (USD MM)

Debtors Turnover Ratio

Highest at 4.56 times

in the last five Semi-Annual periods

MOJO Watch

Company has been able to sell its Debtors faster

Debtors Turnover Ratio

Depreciation

Highest at USD 21.82 MM

in the last five periods

MOJO Watch

The expenditure on assets done by the company may have gone into operation

Depreciation (USD MM)

Depreciation

At USD 21.82 MM has Grown at 46.82%

period on period (QoQ)

MOJO Watch

The expenditure on assets done by the company has gone into productive use which should positively reflect in the future sales

Depreciation (USD MM)

Here's what is not working for Sarepta Therapeutics, Inc.

Pre-Tax Profit

At USD -62.77 MM has Fallen at -293.3%

Year on Year (YoY)

MOJO Watch

Near term Pre-Tax Profit trend is very negative

Pre-Tax Profit (USD MM)

Net Profit

At USD -48.66 MM has Fallen at -251.63%

Year on Year (YoY)

MOJO Watch

Near term Net Profit trend is very negative

Net Profit (USD MM)

Interest

At USD 7.57 MM has Grown at 44.7%

period on period (QoQ)

MOJO Watch

Rising interest cost signifies increased borrowings

Interest Paid (USD MM)

Net Sales

Lowest at USD 399.36 MM

in the last five periods

MOJO Watch

Near term sales trend is negative

Net Sales (USD MM)

Net Sales

Fallen at -14.52%

Year on Year (YoY)

MOJO Watch

Near term sales trend is negative

Net Sales (USD MM)

Interest

Highest at USD 7.57 MM

in the last five periods and Increased by 44.7% (QoQ)

MOJO Watch

Rising interest cost signifies increased borrowings

Interest Paid (USD MM)

Cash and Eqv

Lowest at USD 1,651.13 MM

in the last six Semi-Annual periods

MOJO Watch

Short Term liquidity is deteriorating

Cash and Cash Equivalents

Raw Material Cost

Grown by 26.71% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has deteriorated; this may lead to a fall in profit margin

Raw Material Cost as a percentage of Sales